share_log

Acrivon Therapeutics | DEFR14A: Definitive proxy statement in connection with contested solicitations

SEC announcement ·  May 30, 2023 16:23
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more